{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:01:24Z","timestamp":1774526484324,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dry eye disease is a multifactorial disease; causing various ocular symptoms with potential damage to the ocular surface. Applying hypotensive eye drops are presumed to initiate or exacerbate existing dry eye disease. The purpose of this study was to determine the frequency of signs and symptoms and severity of dry eye disease among glaucoma patients on topical hypotensive medications and controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional comparative study, involving 320 glaucoma patients and controls. Ocular Surface Disease Index (OSDI) symptoms score and Schirmer, tear breakup time and corneal staining tests were used to assess dry eye disease. Data was analyzed using SPSS version 24 software; <jats:italic>p<\/jats:italic>-value less than 0.05 was considered as statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 160 study glaucoma patients, the mean duration of topical hypotensive medication use was 5.2\u2009\u00b1\u20095.21\u2009years (range, 4\u2009months - 32\u2009years). Mild to severe level of OSDI score was found in 122 (76%) glaucoma patients and in 137 (86%) controls (<jats:italic>p<\/jats:italic>\u00a0=\u20090.033). Mild to sever abnormal clinical tests in the glaucoma patients and control, respectively, were 106 (66%) vs 80 (50%) corneal staining (<jats:italic>p<\/jats:italic>\u00a0=\u20090.045), 79 (49%) vs 72 (45%) TBUT (<jats:italic>p<\/jats:italic>\u00a0=\u20090.021), and 91 (57%) vs 83 (52%) Schirmer test (<jats:italic>p<\/jats:italic>\u00a0=\u20090.242). Test results at the level of sever: 2 (1%) vs 0 (0%) corneal staining, 50 (31%) vs 39 (24%) TBUT and 65 (41%) vs 60 (38%) Schirmer test in the glaucoma patents and controls, respectively. Corneal staining and TBUT had correlation with the number of drugs (<jats:italic>p<\/jats:italic>\u00a0=\u20090.004 and 0.031, respectively), and more relationship of the two tests with total number of drops applied per day (<jats:italic>p<\/jats:italic>\u00a0=\u20090.01 and <jats:italic>p<\/jats:italic>\u00a0&lt;\u2009\u00a00.001, respectively). Patients on pilocarpine and timolol had more corneal staining and lower TBUT [(<jats:italic>p<\/jats:italic>\u00a0=\u20090.011 and <jats:italic>p<\/jats:italic>\u00a0&lt;\u2009\u00a00.001) and (<jats:italic>p<\/jats:italic>\u00a0=\u20090.04 and 0.012), respectively].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study has identified glaucoma patients to be more affected by dry eye disease than non-glaucoma patients, and presence of significantly lower TBUT and higher corneal staining in the glaucoma patients on multidrops and multidose per day. We recommend consideration of evaluation and management of DED for glaucoma patients on multidrops and multidose hypotensive medications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-021-01917-3","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T14:02:59Z","timestamp":1617112979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia"],"prefix":"10.1186","volume":"21","author":[{"given":"Miraf","family":"Sahlu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeba T.","family":"Giorgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"3","key":"1917_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II dry eye definition and classification report. Ocul Surf. 2017;15(3):276\u201383. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008.","journal-title":"Ocul Surf"},{"issue":"3","key":"1917_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II dry eye epidemiology report. Ocul Surf. 2017;15(3):334\u201365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003.","journal-title":"Ocul Surf"},{"key":"1917_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","volume":"182","author":"KF Farrand","year":"2017","unstructured":"Farrand KF, Fridman M, Stillman I\u00d6, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2017.06.033.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1917_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/NHH.0000000000000652","volume":"36","author":"PA Rouen","year":"2018","unstructured":"Rouen PA, White ML. Dry eye disease prevalence, assessment, and management. Home Healthcare Now. 2018;36(2):74\u201383. https:\/\/doi.org\/10.1097\/NHH.0000000000000652.","journal-title":"Home Healthcare Now"},{"key":"1917_CR5","first-page":"389","volume-title":"Shields textbook of Glaucoma","author":"RR Allingham","year":"2011","unstructured":"Allingham RR, Damji KF, Freedman S, Moroi SE, Rhee D. Principles of Medical Therapy and Management. In: Shields textbook of Glaucoma. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 389\u201399.","edition":"6"},{"issue":"3","key":"1917_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtos.2018.03.002","volume":"16","author":"ABC Wong","year":"2018","unstructured":"Wong ABC, Wang MTM, Liu K, Prime ZJ, Danesh-Meyer HV, Craig JP. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf. 2018;16(3):289\u201393. https:\/\/doi.org\/10.1016\/j.jtos.2018.03.002.","journal-title":"Ocul Surf"},{"issue":"1","key":"1917_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/ICL.0000000000000544","volume":"45","author":"X Zhang","year":"2019","unstructured":"Zhang X, Vadoothker S, Munir MW, Saeedi O. Ocular surface disease and Glaucoma medications: a clinical approach. Eye Contact Lens. 2019;45(1):11\u20138. https:\/\/doi.org\/10.1097\/ICL.0000000000000544.","journal-title":"Eye Contact Lens"},{"issue":"5","key":"1917_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350\u20135. https:\/\/doi.org\/10.1097\/IJG.0b013e31815c5f4f.","journal-title":"J Glaucoma"},{"issue":"6","key":"1917_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","volume":"29","author":"RD Fechtner","year":"2010","unstructured":"Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618\u201321. https:\/\/doi.org\/10.1097\/ICO.0b013e3181c325b2.","journal-title":"Cornea"},{"issue":"11","key":"1917_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","volume":"27","author":"DA Ammar","year":"2010","unstructured":"Ammar DA, Noecker RJ, Kahook MY. Effects of Benzalkonium chloride-preserved, Polyquad- preserved, and sofZia- preserved topical Glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27(11):837\u201345. https:\/\/doi.org\/10.1007\/s12325-010-0070-1.","journal-title":"Adv Ther"},{"issue":"5","key":"1917_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of ocular surface disease index. Arch Ophthalmol. 2000;118(5):615\u20132. https:\/\/doi.org\/10.1001\/archopht.118.5.615.","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"1917_CR12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/ICO.0b013e318294b0c0","volume":"32","author":"W Ngo","year":"2013","unstructured":"Ngo W, Situ P, Keir N, Korb D, Blackie C, Simpson T. Psychometric propreties and validation of the standard patient evaluation of eye dryness questionnaire. Cornea. 2013;32(9):1204\u201310. https:\/\/doi.org\/10.1097\/ICO.0b013e318294b0c0.","journal-title":"Cornea"},{"issue":"2","key":"1917_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clae.2009.12.010","volume":"33","author":"RL Chalmers","year":"2010","unstructured":"Chalmers RL, Begley CG, Caffery B. Validation of the 5-item dry eye questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnosis. Cont Lens and Anterior Eye. 2010;33(2):55\u201360. https:\/\/doi.org\/10.1016\/j.clae.2009.12.010.","journal-title":"Cont Lens and Anterior Eye"},{"key":"1917_CR14","unstructured":"Foster C.S. Dry Eye Disease (Keratoconjunctivitis Sicca) Workup. https:\/\/emedicine.medscape.com\/article\/1210417-workup. ."},{"key":"1917_CR15","doi-asserted-by":"publisher","unstructured":"Ka\u0161telan S, Tomi\u0107 M, Soldo MK, Salopek-Rabati\u0107 J. How ocular surface disease impacts the Glaucoma treatment outcome. Hindawi Publishing Corp BioMed Res Int http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1155\/2013\/696328. , 2013.","DOI":"10.1155\/2013\/696328"},{"key":"1917_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/0471445428.ch4","volume-title":"Statistical methods for rates and proportions","author":"LA Fleiss","year":"2003","unstructured":"Fleiss LA, Levin B, Cho Paik CM. Determining Sample Sizes Needed to Detect a Difference between Two Proportions. In: Statistical methods for rates and proportions. 3rd ed. New Jersey: John Wiley & Sons, Inc.; 2003. p. 64\u201372.","edition":"3"},{"issue":"9","key":"1917_CR17","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1097\/OPX.0000000000000542","volume":"92","author":"N Ramli","year":"2015","unstructured":"Ramli N, Supramaniam G, Samsudin A, Juana A, Zahari M, Choo MM. Ocular surface disease in Glaucoma: effect of polypharmacy and preservatives. Optom Vis Sci. 2015;92(9):e222\u20136. https:\/\/doi.org\/10.1097\/OPX.0000000000000542.","journal-title":"Optom Vis Sci"},{"issue":"7","key":"1917_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","volume":"22","author":"A Bron","year":"2003","unstructured":"Bron A, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640\u201350. https:\/\/doi.org\/10.1097\/00003226-200310000-00008.","journal-title":"Cornea."},{"issue":"1","key":"1917_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, Mccluskey P. Ocular surface disease and quality of life in patients with Glaucoma. Am J Ophthalmol. 2012;153(1):1\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2011.05.033.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1917_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0161-6420(97)30125-0","volume":"104","author":"OD Schein","year":"1997","unstructured":"Schein OD, Tielsch JM, Mu\u00f1oz B, Bandeen-Roche K, West S. Relation between signs and symptoms of dry eye in the elderly: a population-based perspective. Ophthalmology. 1997;104(9):1395\u2013401. https:\/\/doi.org\/10.1016\/S0161-6420(97)30125-0.","journal-title":"Ophthalmology"},{"issue":"02","key":"1917_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2155-9570.1000334","volume":"5","author":"F Barisic","year":"2014","unstructured":"Barisic F, Krolo I, Suic S, Sesar I, Prskalo M, Mandic Z. Prevalence of ocular surface disease in patients with Glaucoma using topical Antiglaucoma medications. J Clin Exp Ophthalmol. 2014;5(02):2. https:\/\/doi.org\/10.4172\/2155-9570.1000334.","journal-title":"J Clin Exp Ophthalmol"},{"issue":"4","key":"1917_CR22","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1167\/iovs.16-20903","volume":"58","author":"S Datta","year":"2017","unstructured":"Datta S, Baudouin C, Brignole-Baudouin F, Denoyer A, Cortopassi GA. The eye drop preservative Benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells. Invest Ophthalmol Vis Sci. 2017 Apr;58(4):2406\u201312. https:\/\/doi.org\/10.1167\/iovs.16-20903.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1917_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/02713683.2011.562340","volume":"36","author":"WC Stewart","year":"2011","unstructured":"Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391\u20138. https:\/\/doi.org\/10.3109\/02713683.2011.562340.","journal-title":"Curr Eye Res"},{"issue":"2","key":"1917_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1442-9071.2004.00782.x","volume":"32","author":"SH Cha","year":"2004","unstructured":"Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol. 2004;32(2):180\u20134. https:\/\/doi.org\/10.1111\/j.1442-9071.2004.00782.x.","journal-title":"Clin Exp Ophthalmol"},{"key":"1917_CR25","doi-asserted-by":"crossref","unstructured":"Osae AE, Gehlsen U, Horstmann J, Siebelmann S, Stern ME, Kumah DB, Steven P. Epidemiology of dry eye disease in Africa: the sparse information, gaps and opportunities. December, 2016. Elsevier Inc.","DOI":"10.1016\/j.jtos.2017.01.001"},{"issue":"9","key":"1917_CR26","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1097\/OPX.0000000000000667","volume":"92","author":"H Chen","year":"2015","unstructured":"Chen H, Lin C, Tsai Y, Kao C. Association between Glaucoma medication usage and dry eye in Taiwan. Optom Vis Sci. 2015;92(9):e227\u201332. https:\/\/doi.org\/10.1097\/OPX.0000000000000667.","journal-title":"Optom Vis Sci"},{"issue":"6","key":"1917_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/ICO.0000000000001181","volume":"36","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kam WR, Liu Y, Chen X, Sullivan DA. Influence of pilocarpine and timolol on human meibomian gland epithelial cells. Cornea. 2017;36(6):719\u201324. https:\/\/doi.org\/10.1097\/ICO.0000000000001181.","journal-title":"Cornea"},{"issue":"07","key":"1917_CR28","first-page":"120","volume":"06","author":"YC Azuamah","year":"2019","unstructured":"Azuamah YC, Esenwah EC, Ikoro NC, Megwas AU, Ugwuoke AU, Ogbonna GI. Effect of topical 1% Pilocarpine on the ocular tear film pH. Int J Res. 2019;06(07):120\u20138.","journal-title":"Int J Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01917-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-021-01917-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01917-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T14:05:18Z","timestamp":1617113118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-01917-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1917"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-01917-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was undertaken after obtaining ethical clearance from the research and publication ethics committee of the Department of Ophthalmology, School of Medicine, College of Health Sciences, Addis Ababa University. Written informed consent was also obtained from the glaucoma patients and control. The study adhered to the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}